UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy

Ozhirenie i metabolizm, 2024-04, Vol.21 (1), p.42-57

2024

Volltextzugriff (PDF)

Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer

Sibirskiĭ onkologicheskiĭ zhurnal, 2022-03, Vol.21 (1), p.115-121

2022

Volltextzugriff (PDF)

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Medicinskij sovet, 2021-08 (9), p.18-24

2021

Volltextzugriff (PDF)

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

Medicinskij sovet, 2020-12 (20), p.194-198

2020

Volltextzugriff (PDF)

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Medicinskij sovet, 2019-12 (19), p.16-21

2019

Volltextzugriff (PDF)

A case report of immune-related pneumonitis after combined treatment of non small cell lung cancer

Medicinskij sovet, 2020-07 (9), p.258-264

2020

Volltextzugriff (PDF)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

Medicinskij sovet, 2020-07 (9), p.16-24

2020

Volltextzugriff (PDF)

Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients

Medicinskij sovet, 2019-12 (19), p.22-29

2019

Volltextzugriff (PDF)

A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Medical Council, 2018-07 (10), p.9-10

2018

Volltextzugriff (PDF)

Pseudoprogression in patients on immunotherapy

Medicinskij sovet, 2019-06 (10), p.10-14

2019

Volltextzugriff (PDF)

Genetic profile of patients with stage I–IIIA non-small cell lung cancer

Russian Journal of Biotherapy, 2023-04, Vol.22 (1), p.42-48

2023

Volltextzugriff (PDF)

Use of selpercatinib in a patient with RET-mutated non-small cell lung cancer: case report

Sibirskiĭ onkologicheskiĭ zhurnal, 2024-05, Vol.23 (2), p.133-138

2024

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in first versus second line of metastatic non-small cell lung cancer: Real-World Overall Survival

Medicinskij sovet, 2024-07 (10), p.132-137

2024

Volltextzugriff (PDF)

Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy

Sibirskiĭ onkologicheskiĭ zhurnal, 2023-04, Vol.22 (2), p.56-64

2023

Volltextzugriff (PDF)

KRAS-mutated non-small cell lung cancer: new therapy strategies

Sibirskiĭ onkologicheskiĭ zhurnal, 2024-05, Vol.23 (2), p.72-81

2024

Volltextzugriff (PDF)

Body mass index as a possible predictor of the development of immuno-mediated adverse events against the background of therapy with inhibitors of immune response control points

Èndokrinnaâ hirurgiâ, 2023-12, Vol.17 (4), p.33

2023

Volltextzugriff (PDF)

First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia

Medicinskij sovet, 2022-12 (22), p.12-20

2022

Volltextzugriff (PDF)

Systems of response evaluation criteria in solid tumors in immunooncology treatment

Malignant tumours, 2017-01 (1), p.42-46

2017

Volltextzugriff (PDF)

Immune-related encephalopathy at nivolumab effective treatment of lung adenocarcinoma. A case report

Malignant tumours, 2018-05, Vol.8 (1), p.71-76

2018

Volltextzugriff (PDF)

Immunotherapy for non-small cell lung cancer treatment

Malignant tumours, 2016-01 (3), p.17-24

2016

Volltextzugriff (PDF)

IMMUNE-MEDIATED ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS THERAPY

Malignant tumours, 2016-01 (4), p.68-76

2016

Volltextzugriff (PDF)

The concentration of K40 in the water and vegetables of irrigated areas of the Southern Ukraine

Voprosy pitaniia, 1968-07, Vol.27 (4), p.78

1968

Volltextzugriff (PDF)

Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism

Parkinsonism & related disorders, 2021-03, Vol.84, p.112-121

2021

Volltextzugriff (PDF)

Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors

Alʹmanakh klinicheskoĭ medit͡s︡iny, 2022-10, Vol.50 (3), p.187-195

2022

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(37)

Sprache

Englisch
(35)
Russisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy

Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

A case report of immune-related pneumonitis after combined treatment of non small cell lung cancer

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients

A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Pseudoprogression in patients on immunotherapy

Genetic profile of patients with stage I–IIIA non-small cell lung cancer

Use of selpercatinib in a patient with RET-mutated non-small cell lung cancer: case report

Immune Checkpoint Inhibitors in first versus second line of metastatic non-small cell lung cancer: Real-World Overall Survival

Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy

KRAS-mutated non-small cell lung cancer: new therapy strategies

Body mass index as a possible predictor of the development of immuno-mediated adverse events against the background of therapy with inhibitors of immune response control points

First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia

EFFICACY OF NIVOLUMAB (NWO) DURING 2+ LINE TREATMENT AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED REFRACTORY NON-SMALL CELL LUNG CANCER: INTERIM RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY

Systems of response evaluation criteria in solid tumors in immunooncology treatment

Immune-related encephalopathy at nivolumab effective treatment of lung adenocarcinoma. A case report

Immunotherapy for non-small cell lung cancer treatment

IMMUNE-MEDIATED ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS THERAPY

The concentration of K40 in the water and vegetables of irrigated areas of the Southern Ukraine

Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism

Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors

Suchergebnisse filtern